2024
Zhejiang Shengze New Materials was acquired to complement and broaden our business portfolio.
2023
Taizhou Iodine Source Technology was founded to restructure and optimize our iodine-based portfolio. Following the associated shareholding system reform, the company was officially renamed Zhejiang Haizhou Pharmaceutical Co., Ltd.
2020
Anhui Yongshengtang Pharmaceutical was acquired and Gansu Lanzhou Chemical Technology was established, further expanding our business footprint.
2019
Our Contrast Media API production facilities secured cGMP certification.
2017
Ningbo Harvest Polymer Technology Co., Ltd. was acquired to broaden the scope of our business.
2015
Our first EHS audit by a Fortune 500 pharmaceutical company was undertaken and successfully passed.
2014
The company's name was shortened to Zhejiang Haizhou Pharmaceutical Co., Ltd.
2012
The improved waste treatment facility was commissioned.
2011
Maiden clearance from the U.S. FDA was achieved, with a RMB15 million capital injection being approved to upgrade wastewater- and off-gas-treatment systems.
2010
Three new workshops for the production of contrast media intermediates were built.
2009
Zhejiang Jianfeng Haizhou Pharmaceutical Co was designated as a National High-Tech Enterprise; EDQM-approved Guaifenesin API facilities were audited by Wyeth, Johnson & Johnson and Sanofi.
2008
ISO 9001, ISO 14001 and OHSAS 18001 certifications were awarded.
2006
Infrastructure at the Yanhai Industrial Park was extended, with the addition of two multifunctional workshops to improve CMO services.
2005
The production of contrast media intermediates was initiated by Zhejiang Jianfeng Haizhou Pharmaceutical Co.
2004
Zhejiang Jianfeng Haizhou Pharmaceutical Co., Ltd was acquired by the current shareholders, converting the business from a state-owned enterprise to a private entity. As part of the process, cGMP inspection was passed and the GMP certificate for guaifenesin was awarded.
2003
· To meet with the requirements for environmental protection and cater for future expansion, Zhejiang Jianfeng Haizhou Pharmaceutical Co., Ltd. relocated to the Yanhai Industrial Park, a national-level API production base.
1997
The company was renamed as Zhejiang Jianfeng Haizhou Pharmaceutical Co., Ltd.
1996
Production of the expectorant guaifenesin was initiated.
1968
The predecessor to our current company, The Linhai Pharmaceutical Factory, was established to manufacture API’s and produce traditional Chinese medicine preparations.
